ATRA · Atara Biotherapeutics Inc
United States · RS rating 60 · As of 2026-11-03
| Price | 8.20 USD |
|---|---|
| 1-day change | -3.3% |
| RS rating (overall / 1M / 3M / 12M) | 60 / 31 / 58 / 24 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 19 / 24 / 21 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | -10.3% |
| Sales growth Q/Q | -53.8% |
| Distance from 52-week high | +54.7% |
| Market cap (USD) | $40.1M |